Phathom Pharmaceuticals, Inc.

Annual Trend FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net loss ($255.1m) ($129.1m) ($143.9m) ($197.7m) ($201.6m) ($334.3m) ($221.2m)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest ($1.3m) ($255.1m) ($129.1m) ($143.9m) ($197.7m) ($201.6m) ($334.3m) ($221.2m)
Depreciation and amortization $8k $323k $521k $620k $575k $795k $633k $633k $508k
Amortization of debt discount $409k $1.3m $3.6m $2.1m $1.9m $2.2m $3.0m
Depreciation, Depletion and Amortization $8k $323k $521k $620k $575k $795k $633k $508k
Depreciation $0 $8k $300k $500k $600k $575k $795k $633k $508k
Amortization of Debt Issuance Costs $409k $1.3m $3.6m $2.1m $1.9m $2.2m $3.0m
Stock-based compensation $406k $5.8m $16.8m $24.1m $45.0m $24.0m $28.7m $28.7m $27.2m
Share-based Payment Arrangement, Noncash Expense $406k $5.8m $16.8m $24.1m $45.0m $24.0m $28.7m $27.2m
Share-based Payment Arrangement, Expense $406k $5.8m $16.8m $24.1m $45.0m $24.0m $28.7m $27.2m
Nonoperating Income (Expense) ($63k) ($148.9m) ($3.4m) ($8.8m) ($25.3m) ($34.3m) ($56.9m) ($61.3m)
Other Nonoperating Income (Expense) ($10k) ($8k) ($2.1m) ($110k) ($188k) ($8k) ($190k)
Change In Working Capital $5.4m ($13.6m) ($15.3m) ($12.4m) $6.7m
Accounts receivable, net $0 ($1.6m) ($37.2m) ($39.3m) ($46.2m)
Increase (Decrease) in Accounts Receivable $1.6m $37.2m $39.3m ($46.2m)
Change In Receivables $0 ($1.6m) ($37.2m) ($39.3m) ($46.2m)
Changes In Account Receivables $0 ($1.6m) ($37.2m) ($39.3m) ($46.2m)
Inventory reserve $0 $836k $280k
Inventory $0 ($9.4m) ($6.1m) ($11.8m) ($894k)
Increase (Decrease) in Inventories $9.4m $6.1m $11.8m ($894k)
Inventory Write-down $836k $280k
Change In Inventory $0 ($9.4m) ($6.1m) ($11.8m) ($894k)
Accounts payable and accrued expenses $2.3m $24.0m ($9.8m) $8.7m $6.4m $34.9m $34.1m $49.0m
Property and equipment purchases included in accounts payable and accrued expenses $339k $145k $2k $138k $18k $8k $0
Change In Payables And Accrued Expense $7.7m $6.7m $35.5m $34.2m $49.0m
Accrued payment-in-kind interest on debt $3.8m $4.7m
Accrued interest on revenue interest financing liability, net of payments $46.1m $24.3m
Accrued interest $156k $156k $165k $377k $292k $565k $121k
Change In Accrued Expense ($1.0m) $292k $565k $121k ($318k)
Other $322k $823k $1.3m $1.9m $5.1m $5.2m
Prepaid expenses and other current assets ($11.8m) $8.0m $605k ($1.9m) ($8.1m) ($7.7m) $5.5m
Change In Other Current Assets ($118k) ($1.4m) $0 ($1.2m) ($1.4m)
Net cash used in operating activities ($36.5m)
($69.7m) -90.87%
($148.6m) -113.26%
($146.5m) +1.40%
($137.6m) +6.11%
($266.8m) -93.90%
($166.8m) +37.48%
($166.8m) 0.00%
($36.7m) +78.00%
Net Cash Provided by (Used in) Operating Activities ($1.0m)
($36.5m) -3468.91%
($69.7m) -90.87%
($148.6m) -113.26%
($146.5m) +1.40%
($137.6m) +6.11%
($266.8m) -93.90%
($166.8m) +37.48%
($36.7m) +78.00%
Cash flows from investing activities:
Cash paid for property and equipment ($132k) ($1.0m) ($328k) ($1.0m) ($1.6m) ($135k) ($229k)
Payments to Acquire Property, Plant, and Equipment $132k $1.0m $328k $1.0m $1.6m $135k $229k ($219k)
Net cash used in investing activities ($25.2m) ($1.0m) ($328k) ($1.0m) ($1.6m) ($135k) ($229k) ($219k)
Net Cash Provided by (Used in) Investing Activities ($25.2m) ($1.0m) ($328k) ($1.0m) ($1.6m) ($135k) ($229k) ($219k)
Net proceeds from issuance of debt $24.9m $25.0m $96.9m $0 $39.3m $59.4m $0
Repayments of Long-term Debt $54.1m
Proceeds from Issuance of Long-term Debt $24.9m $25.0m $96.9m $0 $39.3m $59.4m $0 $173.2m
Issuance Of Debt $0 $39.3m $59.4m $0 $173.2m
Long Term Debt Issuance $0 $39.3m $59.4m $0 $173.2m
Long Term Debt Payments ($54.1m) $0
Net Issuance Payments Of Debt $0 $39.3m $59.4m $0 ($55.8m)
Repayment Of Debt ($54.1m) $0
Proceeds from issuance of common stock from exercise of stock options $629k $1.9m $0 $124k $1.6m $1.6m $122.0m
Net proceeds from issuance of common stock $24.6m $14.1m $0 $0
Settlement of ESPP liability in common stock $819k $909k $1.4m $2.4m $3.0m
Settlement of 401(k) liability in common stock $903k $1.1m $1.6m $3.7m $5.3m
Proceeds from Issuance of Common Stock $2k $0 $122.0m
Common Stock Issuance $24.6m $155.5m $121.8m $0 $122.0m
Issuance Of Capital Stock $24.6m $155.5m $121.8m $0 $122.0m
Net Other Financing Charges $95.4m $172.7m ($1.9m) ($1.9m)
Net cash (used in) provided by financing activities $304.6m
$114.5m -62.43%
$44.7m -60.94%
$120.0m +168.50%
$367.6m +206.21%
$182.8m -50.28%
($288k) -100.16%
Net Cash Provided by (Used in) Financing Activities $1.9m
$304.6m +15917.14%
$114.5m -62.43%
$44.7m -60.94%
$120.0m +168.50%
$367.6m +206.21%
$182.8m -50.28%
($288k) -100.16%
$69.8m +24344.10%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $879k $242.9m $43.7m ($104.2m) ($27.5m) $228.4m ($84.1m) ($167.3m) $185.3m
Cash and cash equivalents and restricted cash - beginning of period $243.8m $287.5m $183.3m $155.9m $384.3m $300.1m $132.8m
Beginning Cash Position $183.4m $155.9m $384.3m $300.1m $152.4m
Net decrease in cash and cash equivalents and restricted cash $242.9m $43.7m ($104.2m) ($27.5m) $228.4m ($84.1m) ($167.3m)
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Operating right-of-use assets and lease liabilities $51k ($205k) $98k ($238k) $194k $175k $222k
Other long-term assets ($181k) ($203k) $43k ($118k) ($1.4m) $0 ($1.2m)
Net proceeds from underwritten public offering $0 $141.4m $121.8m $0
Payment of employee tax obligations related to vesting of PSUs and RSUs $0 ($1.9m)
Net proceeds from revenue interest financing transaction $95.4m $172.7m $0 $0
Interest paid $1.0m $3.5m $4.1m $7.0m $11.1m $17.3m $21.4m $21.4m $20.1m
Final interest payment fee $2.1m $2.1m $7.5m $0 $2.2m $1.8m $0
Proceeds from Stock Options Exercised $629k $1.9m $0 $124k $1.6m $1.6m
Interest Paid, Excluding Capitalized Interest, Operating Activities $1.0m $3.5m $4.1m $7.0m $11.1m $17.3m $21.4m
General and Administrative Expense $1.2m $6.9m $27.5m $62.7m $101.0m
Income Tax Expense (Benefit) $0 $0 $0 $0 $0 $0 $0 $0
Interest Expense Nonoperating $72.0m $68.1m
Investment Income, Interest $1.1m $1.1m $41k $2.1m $7.9m $15.2m $7.0m
Operating Expenses $1.2m $106.2m $125.7m $135.1m $172.4m $167.8m $324.7m $312.5m
Operating Lease, Expense $500k $700k $1.0m $1.1m $1.1m $1.0m
Cash Flow From Continuing Financing Activities $120.0m $367.6m $182.8m ($288k) $69.8m
Cash Flow From Continuing Investing Activities ($1.0m) ($1.6m) ($135k) ($229k) ($219k)
Change In Account Payable $8.7m $6.4m $34.9m $34.1m $49.0m
Change In Cash Supplemental As Reported ($27.5m) $228.4m ($84.1m) ($167.3m)
Change In Interest Payable $377k $292k $565k $121k ($318k)
Change In Other Working Capital ($238k) $194k $175k $222k $161k
Change In Payable $8.7m $6.4m $34.9m $34.1m $49.0m
Change In Prepaid Assets ($1.9m) ($8.1m) ($7.7m) $5.5m $6.3m
Changes In Cash ($27.5m) $228.4m ($84.1m) ($167.3m) $32.9m
End Cash Position $155.9m $384.3m $300.1m $132.8m $185.3m
Financing Cash Flow $120.0m
$367.6m +206.21%
$182.8m -50.28%
($288k) -100.16%
$69.8m +24344.10%
Free Cash Flow ($147.6m) ($139.2m) ($266.9m) ($167.0m) ($36.9m)
Investing Cash Flow ($1.0m) ($1.6m) ($135k) ($229k) ($219k)
Net PPE Purchase And Sale ($1.0m) ($1.6m) ($135k) ($229k) ($219k)
Other Non Cash Items $21.0m $32.1m $57.2m $37.2m
Proceeds From Stock Option Exercised $0 $124k $1.6m $1.6m $5.7m
Provisionand Write Offof Assets $0 $836k $280k ($539k)
Purchase Of PPE $132k $1.0m $328k ($1.0m) ($1.6m) ($135k) ($229k) ($219k)